Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $5.5 million.

  • Veracyte's Accounts Payables fell 4303.0% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 4303.0%. This contributed to the annual value of $8.6 million for FY2024, which is 3329.21% down from last year.
  • Latest data reveals that Veracyte reported Accounts Payables of $5.5 million as of Q3 2025, which was down 4303.0% from $11.4 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Accounts Payables ranged from a high of $15.7 million in Q1 2025 and a low of $5.5 million during Q3 2025
  • Its 5-year average for Accounts Payables is $11.2 million, with a median of $11.4 million in 2025.
  • Per our database at Business Quant, Veracyte's Accounts Payables surged by 47976.19% in 2021 and then crashed by 4303.0% in 2025.
  • Over the past 5 years, Veracyte's Accounts Payables (Quarter) stood at $12.4 million in 2021, then decreased by 3.63% to $11.9 million in 2022, then increased by 8.66% to $12.9 million in 2023, then tumbled by 33.29% to $8.6 million in 2024, then plummeted by 36.19% to $5.5 million in 2025.
  • Its Accounts Payables was $5.5 million in Q3 2025, compared to $11.4 million in Q2 2025 and $15.7 million in Q1 2025.